Rashmi Bharti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6038485/publications.pdf

Version: 2024-02-01

18	897	17 h-index	21
papers	citations		g-index
23	23	23	1855
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. Cancer Letters, 2016, 375, 51-61.	3.2	184
2	Marine lipopeptide Iturin A inhibits Akt mediated GSK3 \hat{l}^2 and FoxO3a signaling and triggers apoptosis in breast cancer. Scientific Reports, 2015, 5, 10316.	1.6	96
3	Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes. Molecular Pharmaceutics, 2015, 12, 4214-4225.	2.3	68
4	Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy. Cancer Letters, 2017, 388, 292-302.	3.2	65
5	Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene, 2018, 37, 4546-4561.	2.6	61
6	Identification of multifunctional peptides from human milk. Peptides, 2014, 56, 84-93.	1,2	51
7	Microbial amphiphiles: a class of promising new-generation anticancer agents. Drug Discovery Today, 2015, 20, 136-146.	3.2	47
8	Dietary flavone chrysin (5,7-dihydroxyflavone ChR) functionalized highly-stable metal nanoformulations for improved anticancer applications. RSC Advances, 2015, 5, 89869-89878.	1.7	42
9	Metal Ion Ornamented Ultrafast Light-Sensitive Nanogel for Potential in Vivo Cancer Therapy. Chemistry of Materials, 2016, 28, 8598-8610.	3.2	35
10	Differential expression of IL-6/IL-6R and MAO-A regulates invasion/angiogenesis in breast cancer. British Journal of Cancer, 2018, 118, 1442-1452.	2.9	34
11	Therapeutic implication of †lturin A†for targeting MD-2/TLR4 complex to overcome angiogenesis and invasion. Cellular Signalling, 2017, 35, 24-36.	1.7	30
12	Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by †Iturin A†a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium. Scientific Reports, 2017, 7, 17324.	1.6	30
13	Self-assembled cardanol azo derivatives as antifungal agent with chitin-binding ability. International Journal of Biological Macromolecules, 2014, 69, 5-11.	3.6	25
14	Prevention of epithelial to mesenchymal transition in colorectal carcinoma by regulation of the E-cadherin- \hat{l}^2 -catenin-vinculin axis. Cancer Letters, 2019, 452, 254-263.	3.2	25
15	Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. Biochemical Pharmacology, 2019, 164, 1-16.	2.0	24
16	Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach. Tumor Biology, 2015, 36, 9829-9837.	0.8	20
17	Pre-clinical risk assessment and therapeutic potential of antitumor lipopeptide †Iturin A†in an in vivo and in vitro model. RSC Advances, 2016, 6, 71612-71623.	1.7	20
18	BI2536 – A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells. Biomedicine and Pharmacotherapy, 2015, 74, 124-132.	2.5	17